EPAS1 and metabolic dysfunction-associated steatotic liver disease: Overall, significant evidence points toward a steatosis-promoting role for chronic HIF2α activation in liver, likely occurring via inhibition of FAO and upregulation of lipogenesis, though studies investigating the effect of Hif2a deletion in NAFLD on FAO are needed to confirm this.